MedTrace Logo

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

NCT04121468 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-23

No results posted yet for this study

Summary

A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.

Conditions

  • Multiple Sclerosis (MS)

Interventions

DRUG

Metformin

Each tablet contains 500mg of metformin hydrochloride

OTHER

Placebo

Each tablet contains no active drug ingredient

Sponsors & Collaborators

  • Queen's University

    collaborator OTHER

  • Ontario Institute for Regenerative Medicine

    collaborator UNKNOWN

  • Unity Health Toronto

    collaborator OTHER

  • Stem Cell Network

    collaborator OTHER

  • Multiple Sclerosis Society of Canada

    collaborator OTHER

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • E. Ann Yeh, MA, MD, FRCPC, Dip ABPN · The Hospital for Sick Children

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-24
Primary Completion
2027-03-31
Completion
2027-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04121468 on ClinicalTrials.gov